auriniapharma.com Aurinia Pharmaceuticals Inc. > Home

auriniapharma.com
Title: Aurinia Pharmaceuticals Inc. > Home
Keywords: ,DotNetNuke,DNN
Description: Aurinia Pharmaceuticals Inc. > Home RegisterLogin Saturday, July 30, 2016 Home About Aurinia Our Team Management Charles A. Rowland, Jr. Dennis Bourgeault Neil Solomons Michael Martin Robert Huizinga
auriniapharma.com is ranked 4335657 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $4,487. This site has a low Pagerank(0/10). It has 1 backlinks. auriniapharma.com has 43% seo score.

auriniapharma.com Information

Website / Domain: auriniapharma.com
Website IP Address: 64.69.71.162
Domain DNS Server: ns05.domaincontrol.com,ns06.domaincontrol.com

auriniapharma.com Rank

Alexa Rank: 4335657
Google Page Rank: 0/10 (Google Pagerank Has Been Closed)

auriniapharma.com Traffic & Earnings

Purchase/Sale Value: $4,487
Daily Revenue: $12
Monthly Revenue $368
Yearly Revenue: $4,487
Daily Unique Visitors 1,131
Monthly Unique Visitors: 33,930
Yearly Unique Visitors: 412,815

auriniapharma.com WebSite Httpheader

StatusCode 200
Cache-Control private
Content-Type text/html; charset=utf-8
Server Microsoft-IIS/7.5
Date Sun, 31 Jul 2016 03:23:36 GMT

auriniapharma.com Keywords accounting

Keyword Count Percentage
DotNetNuke 0 0.00%
DNN 0 0.00%

auriniapharma.com Traffic Sources Chart

auriniapharma.com Similar Website

Domain Site Title

auriniapharma.com Alexa Rank History Chart

auriniapharma.com aleax

auriniapharma.com Html To Plain Text

Aurinia Pharmaceuticals Inc. > Home RegisterLogin Saturday, July 30, 2016 Home About Aurinia Our Team Management Charles A. Rowland, Jr. Dennis Bourgeault Neil Solomons Michael Martin Robert Huizinga Larry Mandt Board of Directors Richard Glickman Benjamin Rovinski Charles A. Rowland, Jr. Hyuek Joon Lee David R.W. Jayne Gregory M. Ayers Products In Development Voclosporin What is Voclosporin? Lupus Nephritis Why Immunosuppression? Patents Publications About Drug Development For Investors Corporate Governance Corporate Presentations Investor Facts Sheets Investor FAQs Media Coverage News Releases SEDAR Filings Webcasts Partnerships Paladin 3SBio Contact Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis. Our strategy is to leverage our team’s past clinical experience in lupus and the Aspreva Lupus Management Study (ALMS) database in order to inform and guide our clinical development plans within this therapeutic area. Home Home About Aurinia Our Team Management Charles A. Rowland, Jr. Dennis Bourgeault Neil Solomons Michael Martin Robert Huizinga Larry Mandt Board of Directors Richard Glickman Benjamin Rovinski Charles A. Rowland, Jr. Hyuek Joon Lee David R.W. Jayne Gregory M. Ayers Products In Development Voclosporin What is Voclosporin? Lupus Nephritis Why Immunosuppression? Patents Publications About Drug Development For Investors Corporate Governance Corporate Presentations Investor Facts Sheets Investor FAQs Media Coverage News Releases SEDAR Filings Webcasts Partnerships Paladin 3SBio Contact News Releases Aurinia to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York July 28, 2016 read more ... Aurinia Establishes At-The-Market Facility July 22, 2016 read more ... Aurinia Announces Appointment of Head of Communications & Advocacy July 11, 2016 read more ... Aurinia Announces 24 Week Remission Rates From the First Seven Patients in ... AURION June 28, 2016 read more ... Aurinia Announces Closing of US$7 Million Private Placement June 22, 2016 read more ... Aurinia Announces Private Placement June 15, 2016 read more ... View more news releases Click here read more ... Lupus Nephritis – Our Core Strategic Focus Our lead drug, voclosporin, is an immunosuppressant that has utility across many indications. Although voclosporin has been shown to be effective in indications such as prevention of rejection in renal transplantation, it is the lupus market where our company’s key focus now lies. Kidney Inflammation caused by Systemic Lupus Erythematosus (SLE) is referred to as lupus nephritis (LN), and it is estimated that approximately 40-50% of all SLE patients have clinical LN requiring treatment. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels. Poorly controlled LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition. Voclosporin Corporate Governance Corporate Presentations Investor Facts Sheets Investor FAQs Media Coverage SEDAR Filings Webcasts Media Coverage View more media Click here read more ... Home | About Aurinia | Our Team | Products In Development | For Investors | Partnerships | Contact Copyright 2013 by Aurinia Pharmaceuticals Inc. Privacy Statement Terms Of Use

auriniapharma.com Whois

Domain Name: AURINIAPHARMA.COM
Registrar URL: http://www.wildwestdomains.com
Registrant Name: Michael Martin
Registrant Organization: Aurinia Pharmaceuticals
Name Server: NS05.DOMAINCONTROL.COM
Name Server: NS06.DOMAINCONTROL.COM
DNSSEC: unsigned
For complete domain details go to:
http://who.securepaynet.net/whoischeck.aspx?domain=AURINIAPHARMA.COM&prog_id=localt
The data contained in this Registrar's Whois database,
while believed by the registrar to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This information
is provided for the sole purpose of assisting you in obtaining
information about domain name registration records. Any use of
this data for any other purpose is expressly forbidden without
the prior written permission of this registrar. By submitting an
inquiry, you agree to these terms of usage and limitations of warranty.
In particular, you agree not to use this data to allow, enable, or
otherwise make possible, dissemination or collection of this data, in
part or in its entirety, for any purpose, such as the transmission of
unsolicited advertising and solicitations of any kind, including spam.
You further agree not to use this data to enable high volume, automated
or robotic electronic processes designed to collect or compile this data
for any purpose, including mining this data for your own personal or
commercial purposes.
Please note: the owner of the domain name is specified in the "registrant" section.
In most cases, the Registrar is not the owner of domain names listed in this database